

CURRICULUM VITAE
Christopher McCall Jones, PharmD, DrPH, MPH
CAPT, US Public Health Services
Centers for Disease Control and Prevention
National Center for Injury Prevention and Control

Education:

Doctor of Public Health, Health Policy - George Washington University, Washington, DC 20052, May 2019

Master of Public Health, Health Policy and Management - New York Medical College School of Public Health, Valhalla, NY 10595, May 2011

Doctor of Pharmacy - Mercer University School of Pharmacy, Atlanta, GA 30341, May 2006

Bachelor of Science, Biology - Reinhardt College, Waleska, GA 30183, December 2004

Current Federal Employee Status:

Captain (O-6), Commissioned Corps, U.S. Public Health Service

Professional Experience:

National Center for Injury Prevention and Control (NCIPC), Centers for Disease Control and Prevention, (CDC)

Director (December 2022-present) [T42 Executive]

Acting Director (July 2021 to December 2022) [T42 Executive]

Deputy Director (May 2020-present 2021) [T42 Executive]

Position Description:

- As Center Director, oversee all aspects of Center leadership and management, including scientific, policy, programmatic, and budget and operations for a Center of over 700 staff and \$700 million annual budget.
- Provide executive leadership over multiple national prevention programs that provide funding to state, local, tribal, and territorial jurisdictions to advance substance use and overdose prevention, suicide prevention, youth violence and ACEs prevention, and core state injury and violence prevention activities.
- Provide scientific, programmatic, and policy leadership on issues in injury and violence prevention, clinical care implementation and payment policy, service delivery, epidemiology, biostatistics, economics, data science and surveillance, and prevention program and policy strategy and evaluation.
- Drive scientific strategy for the Center's strategic priorities: prevention of substance use and overdose, suicide prevention, prevention of adverse childhood experiences, and community violence prevention.
- Provide focus on critical scientific areas such as: national, state, and community prevention program implementation and evaluation; survey development and data collection; clinical translation and implementation, research methods and analysis; innovative data science methods; implementation and effectiveness of prevention programs, policies, and practices; dissemination of scientific knowledge; and epidemiologic research and public health surveillance to identify risk populations and risk factors.

- Represent CDC in matters of science in appearances and testimony before Congress, HHS, White House, international fora, and other high ranking bodies (i.e., WHO, PAHO and ministries of health).
- Oversee and ensure that all NCIPC programs, scientific research, data collection, publications and communications meet highest standards of quality and integrity.
- Lead and participate in interagency & nongovernmental collaboratives on injury and violence prevention, including engaging with diverse stakeholders to advance prevention science and programs.
- Conduct epidemiological research, program evaluation, and policy research on substance use prevention, mental health, overdose, suicide, and other violence and injury topics to improve prevention activities.
- Routinely engage with key policy and public health organizations such as the National Governors Association (NGA), National Association of State Alcohol and Drug Abuse Directors (NASADAD), Association of State and Territorial Health Officials (ASTHO), Mental Health America (MHA), National Alliance on Mental Illness (NAMI), National Action Alliance for Suicide Prevention, National Association of City and County Health Officials (NACCHO), the National League of Cities (NLC), National Association of Counties (NACo), National Association of Medicaid Directors (NAMd), Council of State and Territorial Epidemiologists (CSTE), Trust for America's Health (TFAH), and PEW charitable trust.
- Engage with healthcare professional society leaders and professional societies to advance clinical practice initiatives and innovations.
- Engage with Executive Branch agencies to advance substance use and mental health prevention initiatives, including the Domestic Policy Council, National Security Council, Office of Management & Budget, Office of National Drug Control Policy, Departments of Justice, Defense, and Veterans Affairs, among others.
- Routinely Brief Members of Congress and their staff.
- Routinely present as keynote or plenary speak on substance use, overdose, ACEs, mental health and suicide, and other injury and violence prevention topics at international, national, and state meetings.
- Provide media interviews with major news outlets, including New York Times, Washington Post, and CNN.

National Center for Injury Prevention and Control (NCIPC), CDC

Senior Advisor & Associate Director, Office of Strategy & Innovation (Sept 2018-May 2020)

Position Description:

- Serve as senior advisor to the Injury Center Director and provide public health counsel on priority injury and violence prevention topics.
- Provide strategic policy and scientific direction and coordination on substance use and overdose prevention, suicide, and adverse childhood experiences (ACEs), among other priority topics in the Injury Center.
- Provide leadership for strategic planning and development of innovations across Injury Center programs.
- Work with Offices and Divisions to develop and maintain ongoing mechanisms for obtaining ideas, and initiatives related to state and national programs, policies, and practices related to injury and violence topics, with a focus on ACEs, suicide, and substance use and overdose prevention.
- Manage a team of scientist and public health practitioners to advance innovative approaches to collecting, linking, and using data and surveillance to inform prevention program and policy efforts, and expand the use of data science tools, methods, and techniques across Injury Center programs.
- Build strategic partnerships to advance public health data and surveillance, and the deployment of data science innovations in the injury and violence prevention field.
- Conduct epidemiological and policy research to improve policy, programs, and clinical practice.
- Oversee budget, hiring, and other management and operation functions for the Office.
- Provide media interviews with major news outlets, including New York Times, Washington Post, and CNN.

National Mental Health and Substance Use Policy Laboratory, Substance Abuse and Mental Health Services Administration (SAMHSA)

Director (Jan 2018-Sept 2018) [SES Equivalent]

Position Description:

- Appointed as the first director of the National Mental Health and Substance Use Policy Laboratory.
- Oversee the development and implementation of the Policy Laboratory, including developing and managing budget, hiring and mentoring staff, and setting priorities for the Policy Lab.
- Oversee all aspects of the Policy Lab, including identifying, coordinating, and facilitating the implementation of policies that will have a significant effect on mental health, mental illness (especially severe mental illnesses such as schizophrenia and schizoaffective disorders), suicide prevention, recovery supports, and the prevention and treatment of substance use disorders.
- Work with the Center for Behavioral Health Statistics and Quality to collect information from grantees under programs operated by SAMHSA in order to evaluate and disseminate information on evidence-based practices and service delivery models.
- Work with the Center for Behavioral Health Statistics and Quality to develop new surveillance systems and enhance existing surveillance systems to improve understanding of substance use and mental health and inform the delivery of clinical and community-based services.
- Lead the development and ongoing maintenance of the Evidence-Based Practices Resource Center, a national repository of evidence-based practices, programs, and policies for substance use and mental health.
- Work collaboratively with SAMHSA leadership and leadership in other Federal agencies to identify priority areas related to research and implementation of evidence-based policies, practices, programs, and clinical service delivery models related to the substance use and mental health prevention, treatment, and recovery.
- Lead the preparation of SAMHSA's Strategic Plan FY2019-FY2023 published in November 2018.
- Maintain liaison and represent SAMHSA in meetings with HHS, with other Federal agencies, Congressional committees, and private organizations concerning behavioral health policy.
- Review programs and activities operated by SAMHSA Centers to: identify any programs or activities that are duplicative; identify any programs or activities that are not evidence-based, effective, or efficient; and formulate recommendations for coordinating, eliminating, or improving them.

U.S. Department of Health and Human Services (HHS), Assistant Secretary for Planning and Evaluation Acting Associate Deputy Assistant Secretary for Science and Data Policy (Dec 2016-Dec 2017) [SES Equivalent]

Director, Division of Science Policy (September 2015-December 2017) [GS-15 Equivalent]

Position Description:

- Oversee the budget and research planning and execution of the research agenda for the Office of Science and Data Policy; manage staff and budget priorities, provide oversight on hiring and meeting ASPE objectives for the Office.
- Oversee the Division of Science Policy which is the ASPE lead on public health and biomedical science policy and programmatic issues and initiatives, including programmatic and policy areas that involve complex or rapidly evolving science and technology. The Division is responsible for policy coordination; long-range planning; legislative development; economic, program, and regulatory analysis and research; and evaluation focused on the HHS science agencies – CDC, FDA, NIH and ASPR.
- Oversee the Division of Data Policy which is responsible for data and statistical policy development and coordination within HHS and serves as the HHS focal point for department-wide data and statistical policy.
- Provide policy counsel and strategic advice to HHS Senior Leaders, including the HHS Secretary and Senior Counselors, and lead the development and implementation of Administration and HHS-level initiatives, including the HHS Opioid Overdose Initiative and the Combatting Antibiotic Resistance Task Force.
- Engage with the White House Domestic Policy Council, Office of Science and Technology Policy, and National Security Council on priority science and public health policy and programmatic issues.

- Conduct epidemiological and policy research, advise on new programmatic efforts, data collections and surveillance systems, and disseminate latest science and research findings to advance HHS strategic goals.

**U.S. Food and Drug Administration (FDA), Office of the Commissioner
Senior Advisor (Feb 2014-Sept 2015) [GS-15 Equivalent]**

Position Description:

- Serve as senior advisor to the Associate Commissioner and FDA Commissioner on priority public health topics and provide public health counsel and recommendations to Agency leadership.
- Serve as Agency lead on substance use and overdose and lead Agency's opioid abuse workgroup. This required extensive interaction and strategic leadership across a diverse group of senior Agency leaders.
- Provide strategic policy direction and analysis on drug abuse and overdose, among other public health topics, to the FDA Commissioner and senior FDA leadership. This included coordinating cross-FDA and cross-HHS activities related to strategic policy and budget planning.
- Conduct quantitative epidemiological, economic, and policy research related to FDA regulated products and public health matters, including approaches to drug safety and risk management, and advising on the development of new surveillance systems and data collection strategies.

**National Center for Injury Prevention and Control, CDC
Senior Scientist (July 2011-Feb 2014) [GS-15 Equivalent]**

Position Description:

- Serve as CDC lead on substance use, misuse, and overdose, and provide strategic policy direction on substance use and overdose prevention programs to the CDC Director and senior CDC leadership.
- Develop CDC's national drug overdose prevention program, including interviewing and hiring staff, identifying budget resources and priorities, securing funding for priority projects and programs.
- Develop and carry out a scientific research agenda to further identify substance use risk factors, evaluate policies and programs at the federal, state, and local level, and enhance surveillance activities.
- Conducted epidemiological and evaluation research to improve policy and clinical practice.
- Provide direct technical assistance to state leadership on strategic policy planning, research, and evaluation activities related to substance abuse and overdose.
- Serve as a lead for CDC on drug abuse and overdose work within Federal Interagency Work Groups.

**White House, Office of National Drug Control Policy
Senior Public Health Advisor (Aug 2010-July 2011; 1 year detail) [GS-15 Equivalent]**

Position Description:

- Provide public health counsel to the Director of ONDCP and Departmental and Agency leadership regarding substance use policy, research, surveillance, and legislative issues.
- Co-lead the development of the President's Prescription Drug Abuse Prevention Plan – the Federal Government roadmap for preventing prescription drug abuse.
- Conduct quantitative and qualitative epidemiological, clinical practice, and policy research to inform national drug policy.
- Work with interagency partners and external organizations to advance President's Drug Control Priorities.

**Center for Drug Evaluation and Research, U.S. Food and Drug Administration (FDA)
Team Leader (Dec 2008-Aug 2010)**

- Oversee all aspects of the Drug Safety and Risk Communication team, including supervising staff, setting work priorities, and ensuring the scientific quality of the team's work.

Peer-Reviewed Publications:

2023

- Larochlle MR, **Jones CM**, Zhang K. Change in opioid and buprenorphine prescribers and prescriptions by specialty, 2016-2021. *Drug Alcohol Depend*. 2023;248:109933.
- Anderson KN, Johns D, Holland KM, Chen Y, Vivolo-Kantor AM, Trinh E, Bitsko RH, Leeb RT, Radhakrishnan L, Bacon S, **Jones CM**. Emergency department visits involving mental health conditions, suicide-related behaviors, and drug overdoses among adolescents – United States, January 2019-February 2023. *MMWR Morb Mortal Wkly Rep*. 2023;72(19):502-512.
- Pickens CM, **Jones CM**, Guy GP, Dailey Govoni T, Green JL. Associations between prescription stimulant use as prescribed, nonmedical use, and illicit stimulant use among adults evaluated for substance use treatment, 2017-2021. *Drug Alcohol Depend Rep*. 2023;7:100153.
- Hoots BE, Li J, Hertz MF, Esser MB, Rico A, Zavala EY, **Jones CM**. Alcohol and other substance use before and during the COVID-19 Pandemic among high school students – Youth Risk Behavior Survey, United States, 2021. *MMWR Suppl*. 2023;72(1):84-92.
- **Jones CM**, Shoff C, Blanco C, Losby JL, Ling SM, Compton WM. Association of receipt of opioid use disorder-related telehealth services and medications for opioid use disorder with fatal drug overdoses among Medicare beneficiaries before and during the COVID-19 pandemic. *JAMA Psychiatry*. 2023;80(5):508-514.
- McLaren N, **Jones CM**, Noonan R, Idaikkadar N, Sumner SA. Trends in stigmatizing language about addiction: A longitudinal analysis of multiple public communication channels. *Drug Alcohol Depend*. 2023;245:109807.
- Tanz LJ, **Jones CM**, Davis NL, Compton WM, Baldwin GT, Han B, Volkow ND. Trends and characteristics of buprenorphine-involved overdose deaths prior to and during the COVID-19 pandemic. *JAMA Netw Open*. 2023;6(1):e2251856.
- Karissa M, Seth P, **Jones CM**. Opportunities for clinicians and health systems to address disparities in overdose deaths by race and ethnicity – Reply. *JAMA* 2023;329(1):95-96.

2022

- Dowell D, Ragan KR, **Jones CM**, Baldwin GT, Chou R. CDC Clinical Practice Guideline for Prescribing Opioids for Pain – United States, 2022. *MMWR Recomm Rep*. 2022;71(3):1-95.
- Dowell D, Ragan KR, **Jones CM**, Baldwin GT, Chou R. Prescribing opioids for pain – the new CDC Clinical Practice Guideline. *N Engl J Med*. 2022;387(22):2011-2013.
- **Jones CM**, Compton WM, Han B, Baldwin G, Volkow ND. Methadone-involved overdose deaths in the United States before and after federal policy changes expanding take-home methadone doses from opioid treatment programs. 2022. *JAMA Psychiatry*. 2022 Sep 1;79(9):932-934.
- **Jones CM**, Shoff C, Hodges K, Blanco C, Losby JL, Ling SM, Compton WM. Receipt of telehealth services, receipt and retention of medications for opioid use disorder, and medically treated overdose among Medicare beneficiaries before and during the COVID-19 pandemic. *JAMA Psychiatry*. 2022 Oct 1;79(10):981-992.
- Sarker A, AL-Garadi MA, Ge Y, Nataraj N, McGlone L, **Jones CM**, Sumner SA. Evidence of the emergence of illicit benzodiazepines from online drug forums. *Eur J Public Health*. 2022;32(6):939-941.
- **Jones CM**, Han B, Seth P, Baldwin G, Compton WM. Increases in methamphetamine injection among treatment admissions. 2022. *Addict Behav*. 2023 Jan;136:107492.
- Han B, Einstein EB, **Jones CM**, Cotto J, Compton WM, Volkow ND. Racial and ethnic disparities in drug overdose deaths in the U.S. during the COVID-19 pandemic. *JAMA Netw Open*. 2022;Sep 1;5(9):e2232314.

- Krawczyk N, Rivera BD, Jent V, Keyes KM, **Jones CM**, Cerda M. Has the treatment gap for opioid use disorder narrowed in the U.S.? A yearly assessment from 2010 to 2019. *Int J Drug Policy*. 2022;Jul 19:103786.
- Simon TR, Kegler SR, Zwald ML, Chen MS, Mercy JA, **Jones CM**, Mercado-Crespo MC, Blair JM, Stone DM. Notes from the Field: Increases in firearm homicide and suicide rates – United States, 2020-2021.
- Seth P, Baldwin GT, Davis NL, **Jones CM**. Clarifying CDC’s efforts to quantify overdose deaths. *Public Health Rep*. 2022;Oct 1:33354922123586.
- Kariisa M, Davis NL, Kumar S, Seth P, Mattson CL, Chowdhury F, **Jones CM**. Vital Signs: Drug overdose deaths, by selected sociodemographic and social determinants of health characteristics – 25 states and the District of Columbia, 2019-2020. *MMWR Morb Mortal Wkly Rep*. 2022;71(29):940-947.
- Sumner SA, Bowen D, Holland K, Zwald ML, Vivolo-Kantor A, Guy GP, Heuett WJ, Pressley DP, **Jones CM**. Estimating weekly national opioid overdose deaths in near real time using multiple proxy data sources. *JAMA Netw Open*. 2022;5(7):e2223033.
- Kariisa M, Seth P, **Jones CM**. Increases in disparities in U.S. drug overdose deaths by race and ethnicity: Opportunities for clinicians and health systems. *JAMA*. 2022;328(5):421-422.
- Hall EW, Rosenberg ES, **Jones CM**, Asher A, Valverde E, Bradley H. Estimated number of injection-involved drug overdose deaths, United States, 2000-2018. *Drug Alcohol Depend*. 2022;234:109428.
- Bradley H, Hall E, Asher A, Furukawa N, **Jones CM**, Shealey J, Buchacz K, Handanagic S, Crepaz N, Rosenberg ES. *Clin Infect Dis*. 2022;Jul 6:ciac543.
- Compton WM, Einstein EB, **Jones CM**. Exponential increases in drug overdose: implications for epidemiology and research. *Int J Drug Policy*. 2022. *Int J Drug Policy*. 2022 Jun;104:103676.
- Hofmeister MG, Asher A, **Jones CM**, Augustine RJ, Burkholder C, Collins J, Foster MA, McBee S, Thoroughman D, Thomasson ED, Weng MK, Spradling PR. Prevalence and types of drugs used among hepatitis A patients during outbreaks associated with person-to-person transmission, Kentucky, Michigan, and West Virginia, 2016-2019. *J Appalach Health*. 2022; 4(1):51-60.
- Kacha-Ochana A, **Jones CM**, Green JL, Dunphy C, Govoni TD, Robbins RS, Guy GP. Characteristics of adults aged ≥ 18 years evaluated for substance use and treatment planning – United States, 2019. *MMWR Morb Mortal Wkly Rep*. 2022;71(23):749-756.
- Sarker A, Al-Garadi MA, Ge Y, Nataraj N, **Jones CM**, Sumner SA. Signals of increasing co-use of stimulants and opioids from online drug forum data. *Harm Reduct J*. 2022;19(1):51.
- Kegler SR, Simon TR, Zwald ML, Chen MS, Mercy JA, **Jones CM**, Mercado-Crespo MC, Blair JM, Stone DM, Ottley PG, Dills J. Vital Signs: Changes in firearm homicide and suicide rates – United States, 2019-2020. *MMWR Morb Mortal Wkly Rep*. 2022;71(19):656-663.
- Brener ND, Bohm MK, **Jones CM**, et al. Use of tobacco products, alcohol, and other substances among high school students during the COVID-19 Pandemic – Adolescent Behaviors and Experiences Survey, United States, January-June 2021. *MMWR Suppl*. 2022;71(3):8-15.
- Zhang K, **Jones CM**, Compton WM, Guy GP, Evans ME, Volkow ND. Association between receipt of antidepressants and retention in buprenorphine treatment for opioid use disorder: a population-based retrospective cohort study. *J Clin Psychiatry*. 2022;83(3):21m14001.
- Sarker A, Nataraj N, Sui W, Li S, **Jones CM**, Sumner SA. Concerns among people who use opioids during the COVID-19 pandemic: a natural language processing analysis of social media posts. *Subst Abuse Treat Prev Policy*. 2022;17(1):16.
- Seitz AE, Janiszewski KA, Guy GP, Tapscott RT, Einstein EB, Meyer TE, Tierney J, Staff J, **Jones CM**, Compton WM. Evaluating opioid analgesic prescribing limits: A narrative review. *Pharmacoepidemiol Drug Saf*. 2022. Mar 5.
- Ehlman DC, Yard E, Stone DM, **Jones CM**, Mack KA. Changes in suicide rates- United States, 2019 and 2020. *MMWR Morb Mortal Wkly Rep*. 2022;71(8):306-312.

- ElSherief M, Sumner SA, **Jones CM**, Law RK, Kacha-Ochana A, et al. Characterizing and identifying the prevalence of web-based misinformation relating to medication for opioid use disorder: Machine Learning Approach. *J Med Internet Res*. 2021;23(12):e30753.

2021

- **Jones CM**, Houry D, Han B, Baldwin G, Vivolo-Kantor A, Compton WM. Methamphetamine use in the United States: epidemiological update and implications for prevention, treatment, and harm reduction. *Ann NY Acad Sci*. 2021. Sep24. Doi:10.1111/nyas.14688.
- Jiang X, Guy GP, Dunphy C, Pickens CM, **Jones CM**. Characteristics of adults reporting illicitly manufactured fentanyl or heroin use or prescription opioid misuse in the United States, 2019. *Drug Alcohol Depend*. 2021. Oct 30;229(Pt A):109160.
- Broz D, Carnes N, Chapin-Bardales J, Des Jarlais DC, Handangic S, **Jones CM**, McClung RP, Asher AK. Syringe services programs' role in ending the HIV Epidemic in the U.S.: Why we cannot do it without them. *Am J Prev Med*. 2021.61(5 Suppl 1):S118-S129.
- Han B, **Jones CM**, Einstein EB, Compton WM. Trends in and characteristics of buprenorphine misuse among adults in the U.S. *JAMA Netw Open*. 2021;4(1):e2129409.
- Dunphy C, Zhang K, Guy GP, **Jones CM**. Naloxone dispensing among the commercially insured population in the United States from 2015 to 2018. *Prev Med*. 2021;153:106820.
- Han B, Compton WM, **Jones CM**, Einstein EB, Volkow ND. Methamphetamine use, methamphetamine use disorder, and associated overdose deaths among US adults. *JAMA Psychiatry*. 2021. Sep 22.doi: 10.1001/jamapsychiatry.2021.2588.
- Sumner SA, Ferguson B, Bason B, Dink J, Yard E, Hertz M, Hilkert B, Holland K, Mercado-Crespo M, Tang S, **Jones CM**. Association of online risk factors with subsequent youth suicide-related behaviors in the U.S. *JAMA Netw Open*. 2021. Sep1;4(9):e2125860.
- **Jones CM**, Diallo MM, Vythilingam M, Schier JG, Eisenstat M, Compton WM. Characteristics and correlates of U.S. clinicians prescribing buprenorphine for opioid use disorder treatment using expanded authorities during the COVID-19 pandemic. *Drug Alcohol Depend*. 2021;225:108783.
- Compton WM, **Jones CM**. Substance use among men who have sex with men. *N Engl J Med*. 2021;385(4):352-356.
- Han B, **Jones CM**, Einstein EB, Powell PA, Compton WA. Use of medications for alcohol use disorder in the US: results from the 2019 National Survey on Drug Use and Health. *JAMA Psychiatry*. 2021;78(8):922-924.
- Trivers KF, Watson CV, Neff LJ, **Jones CM**, Hacker K. Tetrahydrocannabinol (THC)-containing e-cigarette, or vaping, product use behaviors among adults after the onset of the 2019 outbreak of e-cigarette, or vaping, product use-associated lung injury (EVALI). *Addict Behav*. 2021;121:106990.
- Dunphy C, Peterson C, Zhang K, **Jones CM**. Do out-of-pocket costs influence retention and adherence to medications for opioid use disorder? *Drug Alcohol Depend*. 2021;225:108784.
- Wright AP, **Jones CM**, Chau DH, Gladden MR, Sumner SA. Detection of emerging drugs involved in overdose via diachronic word embeddings of substances discussed on social media. *J Biomed Inform*. 2021;119:103824.
- Mustaquim D, **Jones CM**, Compton WM. Trends and correlates of cocaine use among adults in the United States, 2006-2019. *Addict Behav*. 2021;120:106950.
- Tang S, **Jones CM**, Wisdom A, Lin HC, Bacon S, Houry D. Adverse childhood experiences and stimulant use disorders among adults in the United States. *Psychiatry Res*. 2021;299:113870.
- Guy GP, Strahan AE, Haegerich T, Losby JL, Ragan K, Evans ME, **Jones CM**. Concurrent naloxone dispensing among individuals with high-risk opioid prescriptions, USA, 2015-2019. *J Gen Intern Med*. 2021 Mar 9. Doi:10.1007/s11606-021-06662-3.
- Wilkins NJ, Clayton HB, **Jones CM**, Brown M. Current prescription opioid misuse and suicide risk behaviors among high school students. *Pediatrics*. 2021;147(4):e2020030601.

- Stone DM, **Jones CM**, Mack KA. Changes in suicide rates – United States, 2018-2019. *MMWR Morb Mortal Wkly Rep.* 2021;70(8):261-268.
- **Jones CM**, Bekheet F, Park JN, Alexander GC. The evolving overdose epidemic: synthetic opioids and rising stimulant-related harms. *Epidemiol Rev.* 2021;42(1):154-166.
- Stein BD, Smart R, **Jones CM**, Sheng F, Powell D, Sorbero M. Individual and community factors associated with naloxone co-prescribing among long-term opioid patients: a retrospective analysis. *J Gen Intern Med.* 2021. Feb 17. Online ahead of print.
- Stein BD, **Jones CM**, Smart R, Sheng F, Sorbero M. Patient, prescriber, and community factors associated with filled naloxone prescriptions among patients receiving buprenorphine 2017-18. *Drug Alcohol Depend.* 2021. Feb3. Online ahead of print.
- **Jones CM**, Board AR, Guy G. Comparing actual and forecasted numbers of unique patients dispensed select medications for opioid use disorder, opioid overdose reversal, and mental health, during the COVID-19 pandemic, United States, January 2019 to May 2020. *Drug Alcohol Depend.* 2021;219:108846.
- Holland KM, **Jones CM**, Vivolo-Kantor AM, Idaikkadar N, Zwald M, Hoots B, et al. Trends in U.S. emergency department visits for mental health, overdose, and violence-related outcomes before and during the COVID-19 pandemic. *JAMA Psychiatry.* 2021;78(4):372-379.

2020

- King BA, **Jones CM**, Baldwin GT, Briss PA. E-cigarette, or vaping, product use-associated lung injury: looking back, moving forward. *Nicotine Tob Res.* 2020;22(Supplement_1):S96-S99.
- Vivolo-Kantor AM, Hoots BE, Seth P, **Jones CM**. Recent trends and associated factors of amphetamine-type stimulant overdoses in emergency departments. *Drug Alcohol Depend.* 2020;216:108323.
- Board AR, Guy G, **Jones CM**, Hoots B. Trends in stimulant dispensing by age, sex, state of residence, and prescriber specialty – United States, 2014-2019. *Drug Alcohol Depend.* 2020;217:108297.
- **Jones CM**, Clayton HB, Deputy NP, Roehler DR, Ko JY, et al. Prescription opioid misuse and use of alcohol and other substances among high school students – Youth Risk Behavior Survey, United States, 2019. *MMWR Suppl.* 2020;69(1):38-46.
- **Jones CM**, Noonan RK, Compton WM. Prevalence and correlates of ever having a substance use problem and substance use recovery status among adults in the United States, 2018. *Drug Alcohol Depend.* 2020 Sep 1;214:108169.
- Sumner SA, Haegerich TM, **Jones CM**. Temporal trends in online posts about vaping of cannabis products. *J Addict Med.* 2020. Aug 4. Online ahead of print.
- Allen ST, Grieb SM, White RH, O'Rourke A, Kilkenny ME, **Jones CM**, Latkin C, Sherman SG. Human Immunodeficiency Virus testing among people who inject drugs in rural West Virginia. *J Infect Dis.* 2020;222(Supplement_5):S346-S353.
- Levitt A, Mermin J, **Jones CM**, See I, Butler JC. Infectious diseases and injection drug use: public health burden and response. *J Infect Dis.* 2020;222(Supplement_5):S213-S217.
- Roehler DR, Guy GP, **Jones CM**. Buprenorphine prescription dispensing rates and characteristics following federal changes in prescribing policy, 2017-2018: A cross-sectional study. *Drug Alcohol Depend.* 2020. May 25;213:108083. doi: 10.1016/j.drugalcdep.2020.108083. Online ahead of print
- Reagan-Steiner S, Matkovic GJ, Ritter JM, Shieh WJ, Martines RB, Werner AK, Lynfield R, Holzbauer S, Bullock H, Denison AM, Bhatnager J...**Jones CM**, et al. Pathological findings in suspected cases of e-cigarette, or vaping, product use-associated lung injury (EVALI): a case series. *Lancet Respir Med.* 2020;Aug4:S2213-2600.
- Werner AK, Koumans EH, Chatham-Stephens K, Salvatore PP, Armatas C, Byers P, Clark CR, Ghinai I, Holzbauer SM, Navarette KA, Danielson ML, Ellington S, Moritz ED, Petersen EE, Kiernan EA, Baldwin GT, Briss P, **Jones CM**, et al. Hospitalizations and deaths associated with EVALI. *N Engl J Med.* 2020;382(17):1589-1598.

- Adkins SH, Anderson KN, Goodman AB, Twentyman E, Danielson ML, Kimball A, Click ES, Ko JY, Evans ME, Weissman DN, Melstrom P, Kiernan E, Krishnasamy V, Rose DA, **Jones CM** et al., Demographics, substance use behaviors, and clinical characteristics of adolescents with e-cigarette, or vaping, product use-associated lung injury (EVALI) in the United States in 2019. *JAMA Pediatr.* 2020. 174(7):e200756.
- **Jones CM**, Mustaquim D, Compton WM. Patterns and correlates of methamphetamine use among adults in the United States, 2015-2018. *MMWR Morb Mortal Wkly Rep.* 2020;69(12):317-323.
- Compton WM, **Jones CM**. Commentary on Chan & Hall (2020): Advances in specifying cannabis consumption. *Addiction.* 2020;115(6):1187-1188.
- Smart R, Geiger CK, **Jones CM**, Stein BD. Prescribers and naloxone pharmacy claims. *J Gen Intern Med.* 2020. Mar 24.doi:10.1007/s11606-020-05791-5.
- **Jones CM**, Olsen EO, O'Donnell J, Mustaquim D. Resurgent methamphetamine use at treatment admission in the United States, 2008-2017. *Am J Pub Health.* 2020;110(4):509-516.
- King BA, **Jones CM**, Baldwin GT, Briss PA. The EVALI and Youth-Vaping Epidemics — Implications for Public Health. *N Engl J Med.* 2020;382(8):689-691.
- Compton WM, **Jones CM**, Underwood N. Reducing negative consequences from use of methamphetamine. *Addiction.* 2020;115(6):1190-1191.
- Krishnasamy VP, Hallowell BD, Ko JY, Board A, Hartnett KP, Salvatore PP, Danielson M, Kite-Powell A, Twentyman E, Kim L, Cyrus A, Wallace M, Melstrom P, Haag B, King BA, Briss P, **Jones CM**, et al. Update: Characteristics of a nationwide outbreak of E-cigarette, or vaping, product use-associated lung injury – United States, August 2019-January 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(3):90-94.
- Ghinai I, Navon L, Gunn JKL, Duca LM, Brister S, Love S, Brink R, Fajardo G, Johnson J, Saathoff-Huber L, King BA, **Jones CM**, Krishnasamy VP, Layden JE. Characteristics of persons who report using only nicotine-containing products among interviewed patients with E-cigarette, or vaping, product use-associated lung injury – Illinois, August-December 2019. *MMWR Morb Mortal Wkly Rep.* 2020;69(3):84-89.
- Ellington S, Salvatore PP, Ko J, Danielson M, Kim L, Cyrus A, Wallace M, Board A, Krishnasamy V, King BA, Rose D, **Jones CM**, Pollack LA et al. Update: product, substance-use, and demographic characteristics of hospitalized patients in a nationwide outbreak of e-cigarette, or vaping, product use-associated lung injury – United States, August 2019-January 2020. *MMWR Morb Mortal Wkly Rep.* 2020 Jan 17;69(2):44-49.

2019

- **Jones CM**, Merrick MT, Houry DE. Identifying and preventing adverse childhood experiences: implications for clinical practice. *JAMA.* 2019 Nov 5. Doi:10.1001/jama.2019.18499. [Epub ahead of print].
- **Jones CM**, Byrd DJ, Clarke TJ, Campbell TB, Ohuoha C, McCance-Katz EF. Characteristics and current clinical practices of opioid treatment programs in the United States. *Drug Alcohol Depend.* 2019;205:107616.
- **Jones CM**, Underwood JM, Volkow ND. Challenging the association of marijuana laws with teen marijuana use. *JAMA Pediatr.* 2019 Nov 11. Doi:10.1001/jamapediatrics.2019.4235. [Epub ahead of print].
- Madras BK, Han B, Compton WM, **Jones CM**, Lopez EI, McCance-Katz EF. Associations of parental marijuana use with offspring marijuana, tobacco, and alcohol use, and opioid misuse. *JAMA Netw Open.* 2019;2(11):e1916015.
- Mikosz CA, Danielson M, Anderson KN, Pollack LA, Currie DW, Njai R, Evans ME, Goodman AB, Twentyman E, Wiltz JL, Rose DA, Krishnasamy V, King BA, **Jones CM**, et al. Characteristics of patients experiencing rehospitalization or death after hospital discharge in a nationwide outbreak of e-cigarette, or vaping, product use-associated lung injury – United States, 2019. *MMWR Morb Mortal Wkly Rep.* 2020;68(5152):1183-1188.
- Evans ME, Twentyman E, Click ES, Goodman AB, Weissman DN, Kiernan E, Hovevar SA, Mikosz CA, Danielson M, Anderson KN, Ellington S, Lozier MJ, Pollack LA, Rose DA, Krishnasamy V, **Jones CM**, et

al. Update: interim guidance for health care professionals evaluating and caring for patients with suspected e-cigarette, or vaping, product use-associated lung injury and for reducing the risk for rehospitalization and death following hospital discharge – United States, December 2019. *MMWR Morb Mortal Wkly Rep.* 2020;68(5152):1189-1194.

- Blount BC, Karwowski MP, Shields PG, Morel-Espinosa M, Valentin-Blasini L, Gardner M, Braselton M, Brosius CR, Caron KT, Chambers D, Corstvet J, Cowan E, De Jesús VR, Espinosa P, Fernandez C, Holder C, Kuklenyik Z, Kusovschi JD, Newman C, Reis GB, Rees J, Reese C, Silva L, Seyler T, Song MA, Sosnoff C, Spitzer CR, Tevis D, Wang L, Watson C, Wewers MD, Xia B, Heitkemper DT, Ghinai I, Layden J, Briss P, King BA, Delaney LJ, **Jones CM**, et al. Vitamin E acetate in bronchoalveolar lavage fluid associated with EVALI. *N Engl J Med.* 2019 Dec 20. Doi:10.1056/NEJMoa1916433. [Epub ahead of print].
- Lozier MJ, Wallace B, Anderson K, Ellington S, **Jones CM**, Rose D, Baldwin G, King BA, Briss P, Mikosz CA. Update: demographic, product, and substance-use characteristics of hospitalized patients in a nationwide outbreak of e-cigarette, or vaping, product use-associated lung injuries – United States, December 2019. *MMWR Morb Mortal Wkly Rep.* 2019;68(49):1142-1148.
- Chatham-Stephens K, Roguski K, Jang Y, Cho P, Jatlaoui TC, Kabbani S, Glidden E, Ussery EN, Trivers KF, Evans ME, King BA, Rose DA, **Jones CM**, et al. Characteristics of hospitalized and nonhospitalized patients in a nationwide outbreak of e-cigarette, or vaping, product use-associated lung injury – United States, November 2019. *MMWR Morb Mortal Wkly Rep.* 2019;68(46):1076-1080.
- Jatlaoui TC, Wiltz JL, Kabbani S, Siegel DA, Koppaka R, Montandon M, Adkins SH, Weissman DN, Koumans EH, O'Hegarty M, O'Sullivan MC, Ritchey MD, Chatham-Stephens K, Kiernan EA, Layer M, Reagan-Steiner S, Legha JK, Shealy K, King BA, **Jones CM**, et al. Update: interim guidance for health care providers for managing patients with suspected e-cigarette, or vaping, product use-associated lung injury – United States, November 2019. *MMWR Morb Mortal Wkly Rep.* 2019;68(46):1081-1086.
- Navon L, **Jones CM**, Ghinai I, King BA, Briss PA, Hacker KA, Layden JE. Risk factors for e-cigarette, or vaping, product use-associated lung injury (EVALI) among adults who use e-cigarette, or vaping, products – Illinois, July-October 2019. *MMWR Morb Mortal Wkly Rep.* 2019;68(45):1034-1039.
- Blount BC, Karwowski MP, Morel-Espinosa M, Rees J, Sosnoff C, Cowan E, Gardner M, Wang L, Valentin-Blasini L, Silva L, De Jesus VR, Kuklenyik Z, Watson C, Seyler T, Xia B, Chambers D, Briss P, King BA, Delaney L, **Jones CM**, et al. Evaluation of bronchoalveolar lavage fluid from patients in an outbreak of e-cigarette, or vaping, product use-associated lung injury – 10 states, August-October 2019. *MMWR Morb Mortal Wkly Rep.* 2019;68(45):1040-1041.
- **Jones CM**, Underwood N, Compton W. Increases in methamphetamine use among heroin treatment admissions in the United States, 2008-2017. *Addiction.* 2019. Doi:10.1111/add.14812.
- Merrick MT, Ford DC, Ports KA, Guinn AS, Chen J, Klevens J, Metzler M, **Jones CM**, Simon TR, Daniel VM, Ottley P, Mercy JA. Vital Signs: estimated proportion of adult health problems attributable to adverse childhood experiences and implications for prevention – 25 states, 2015-2017. *MMWR Morb Mortal Wkly Rep.* 2019;68(44):999-1005.
- Moritz ED, Zapata LB, Lekachvili A, Glidden E, Annor FB, Werner AK, Ussery EN, Hughes MM, Kimball A, DeSisto CL, Kenemer B, Shamout M, Garcia MC, Regan-Steiner S, Petersen EE, Koumans EH, Ritchet MD, King BA, **Jones CM**, et al. Update: Characteristics of patients in a national outbreak of e-cigarette, or vaping, product use-associated lung injuries – United States, October 2019. *MMWR Morb Mortal Wkly Rep.* 2019;68(43):985-989.
- Lippold KM, **Jones CM**, Olsen EO, Giroir BP. Racial/ethnic and age group differences in opioid and synthetic opioid-involved overdose deaths among adults aged ≥ 18 years in metropolitan areas – United States, 2015-2017. *MMWR Morb Mortal Wkly Rep.* 2019;68(43):967-973.
- Smart R, Geiger CK, **Jones CM**, Stein BD. An observational study of retail pharmacy naloxone prescriptions: differences across provider specialties and patient populations. *J Gen Intern Med.* 2019. Doi:10.1007/s11606-019-05448-y.

- Siegel DA, Jatlaoui TC, Koumans EH, Kiernan EA, Layer M, Cates JE, Kimball A, Weissman DN, Petersen EE, Reagan-Steiner S, Godfred-Cato S, Moulja D, Moritz E, Lehnert JD, Mitchko J, London J, Zaki SR, King BA, **Jones CM**, et al. Update: interim guidance for health care providers evaluating and caring for patients with suspected e-cigarette, or vaping, product use associated lung injury – United States, October 2019. *MMWR Morb Mortal Wkly Rep*. 2019;68(41):919-927.
- Perrine CG, Pickens CM, Boehmer TK, King BA, **Jones CM**, DeSisto CL, Duca LM, Lekachvili A, et al. Characteristics of a multistate outbreak of lung injury associated with e-cigarette use, or vaping – United States, 2019. *MMWR Morb Mortal Wkly Rep*. 2019;68(39):860-864.
- Haegerich TM, **Jones CM**, Cote PO, Robinson A, Ross L. Evidence for state, community, and systems-level prevention strategies to address the opioid crisis. *Drug Alcohol Depend*. 2019;204:107563.
- **Jones CM**, Warner M, Hedegaard H, Compton W. Data quality considerations when using county-level opioid overdose death rates to inform policy and practice. *Drug Alcohol Depend*. 2019;204:107549.
- **Jones CM**, Compton WM, Vythilingam M, Giroir B. Naloxone co-prescribing to patients receiving prescription opioids in the Medicare Part D program, United States, 2016-2017. *JAMA* 2019;322(5):462-464.
- Guy GP, Haegerich TM, Evans ME, Losby JL, Young R, **Jones CM**. Vital Signs: pharmacy-based naloxone dispensing – United States, 2012-2018. *MMWR Morb Mortal Wkly Rep*. 2019;68(31):679-686.
- Compton WM, **Jones CM**. Epidemiology of the U.S. opioid crisis: the importance of the vector. *Ann NY Acad Sci*. 2019;doi:10.1111/nyas.14209.
- Compton WM, Han B, **Jones CM**. Cannabis use disorders among adults in the United States during a time of increasing use of cannabis. *Drug Alcohol Depend*. 2019;204:107468.
- Compton WM, **Jones CM**, Baldwin GT, Harding FM, Blanco C, Wargo EM. Targeting youth to prevent later substance use disorder: an underutilized response to the U.S. opioid crisis. *Am J Public Health*. 2019;109(S3):S185-S189.
- **Jones CM**. Syringe services programs: an examination of legal, policy, and funding barriers in the midst of the evolving opioid crisis in the U.S. *Int J Drug Policy*. 2019;70:22-32.
- **Jones CM**, McCance-Katz EF. Co-occurring substance use and mental disorders among adults with opioid use disorder. *Drug Alcohol Depend*. 2019;197:78-82.
- **Jones CM**, McCance-Katz EF. Relationship between recency and frequency of youth cannabis use on other substance use. *J Adolesc Health*. 2019;64(3):411-413.
- **Jones CM**, McCance-Katz EF. Characteristics and prescribing practices of clinicians recently waived to prescribe buprenorphine for the treatment of opioid use disorder. *Addiction*. 2019;114(3):471-482.
- Han B, Compton W, Blanco C, **Jones CM**. Time since first cannabis use and 12-month prevalence of cannabis use disorder among youth and emerging adults in the United States. *Addiction*. 2019;114(4):698-707.
- Compton W, Han B, Blanco C, **Jones CM**. Misuse of immediate-release stimulants: response to Diller. *Am J Psychiatry*. 2019;176(1):77-78.

2018

- Saloner B, Levin J, Chang HY, **Jones C**, Alexander GC. Changes in buprenorphine-naloxone and opioid pain reliever prescriptions after the Affordable Care Act Medicaid expansion. *JAMA Netw Open*. 2018;1(4):e181588.
- Heyward J, **Jones CM**, Compton WM, et al. Coverage of nonpharmacologic treatments for low back pain among U.S. public and private insurers. *JAMA Network Open*. 2018;1(6):e183044.
- **Jones CM**, Compton WM, Einstein E. Changes in synthetic opioid involvement in drug overdose deaths in the United States, 2010-2016. *JAMA*. May 1;319(17):1819-1821.
- Han B, Compton W, Blanco C, **Jones CM**. Correlates of prescription opioid use, misuse, use disorders, and motivations for misuse among U.S. adults. *J Clin Psychiatry*. 2018;79(5). *J Clin Psychiatry*.

- Murimi IB, Chang HY, Bicket M, **Jones CM**, Alexander GC. Using trajectory models to assess the effect of hydrocodone upcheduling among chronic hydrocodone users. *Pharmaco Epidemiol Drug Saf*. 2018. Accepted.
- Blanco C, Han B, **Jones CM**, Johnson K, Compton WM. Prevalence and correlates of benzodiazepine use, misuse, and use disorders among adults in the United States. *J Clin Psychiatry*. 2018;79(6).
- Johnson K, **Jones C**, Compton W, Baldwin G, Fan J, Mermin J, Bennet J. Federal response to the opioid crisis. *Curr HIV/AIDS Rep*. 2018;15(4):293-301.
- Lin DH, **Jones CM**, Compton WM, Heyward et al. Prescription drug coverage for treatment of low back pain among US Medicaid, Medicare Advantage, and Commercial Insurers. *JAMA Network Open*. 2018;1(2):e180235.
- Compton WM, Han B, Blanco C, Johnson K, **Jones CM**. Prevalence and correlates of prescription stimulant use, misuse, use disorders, and motivations for misuse among adults in the United States. *Am J Psychiatry*. 2018. Apr 16:appiajp201817091048.
- Han B, Compton WM, Blanco C, **Jones CM**. Trends in and correlates of medical marijuana use among adults in the United States. *Drug Alcohol Depend*. 2018 May 1;186:120-129.
- Han B, Compton WM, Blanco C, **Jones CM**. Prescription opioid use, misuse, and use disorders in U.S. adults. *Ann Intern Med*. 2018;168(5):383-384.
- Zivin K, White JO, Chao S, Christensen AL, Horner L, Petersen DM, Hobbs MR, Capreol G, Halbritter KA, **Jones CM**. Implementing electronic health record default settings to reduce opioid overprescribing: A pilot study. *Pain Med*. 2018 Jan 9. doi: 10.1093/pm/pnx304.
- Change HY, Murimi IB, **Jones CM**, Alexander GC. Relationship between high-risk patients receiving prescription opioids and high-volume opioid prescribers. *Addiction*. 2018;113(4):677-686.
- Heins SE, Sorbero MJ, **Jones CM**, Dick AW, Stein BD. High-risk prescribing to Medicaid enrollees receiving opioid analgesics: individual and county-level factors. *Subst Use Misuse*. 2018;Jan5:1-11.

2017

- Compton WM, **Jones CM**, Stein JB, Wargo EM. Promising roles for pharmacists in addressing the U.S. opioid crisis. *Res Social Adm Pharm*. 2017. Dec 31. Pii:S1551-7411(17)30977-4.
- **Jones CM**. Trends and Key Correlates of Prescription Opioid Injection Misuse in the United States Addictive Behaviors. *Addictive Behaviors*. 2017 Nov 22;78:145-152.
- Mack KA, **Jones CM**, Ballesteros MF. Illicit drug use, illicit drug use disorders, and drug overdose deaths in metropolitan and nonmetropolitan areas- United States. *Am J Transplant*. 2017;17(12):3241-3252.
- Thomas CP, Doyle E, Kriener PW, **Jones CM**, Dubenitz J, Horan A, Stein BD. Prescribing patterns of buprenorphine waived physicians. *Drug Alcohol Depend*. 2017;181:213-218.
- Mack KA, **Jones CM**, Ballesteros MF. Illicit drug use, illicit drug use disorders, and drug overdose deaths in metropolitan and nonmetropolitan areas – United States. *MMWR Surveill Summ*. 2017;66(19):1-12.
- Han B, **Jones CM**, Blanco C, Compton WM. National trends in and correlates of nonmedical use of prescription stimulants, nonmedical use frequency, and use disorders. *J Clin Psychiatry*. 2017;.pii17m11760.
- Han B, Compton WM, Blanco C, Crane E, Lee J, **Jones CM**. Prescription opioid use, misuse, and use disorders in U.S. adults; 2015 National Survey on Drug Use and Health. *Ann Intern Med*. 2017. Aug 1. Doi: 10.7326/M17-0865.
- Han B, Compton WM, **Jones CM**, Blanco C. Cannabis use and cannabis use disorders among youth in the United States, 2002-2014. *J Clin Psychiatry*. 2017 Jul 5. Pii:16m10948.
- **Jones CM**, Christensen A, Gladden RM. Increases in prescription opioid injection among treatment admissions in the United States, 2004-2013. *Drug Alcohol Depend*. 2017 Jul 1:176:89-95.
- Mack KA, **Jones CM**, McClure RJ. Physician Dispensing of Oxycodone and Other Commonly Used Opioids, 2000-2015, United States. *Pain Med*. 2017 Mar 15. doi: 10.1093/pm/pnx007.

- **Jones CM**, Baldwin GT, Compton WM. Recent increases in cocaine-related overdose deaths and the role of opioids. *Am J Public Health*. 2017;107(3):430-432.
- **Jones CM**. The paradox of decreasing nonmedical opioid analgesic use and increasing abuse or dependence – An assessment of demographic and substance use trends, United States, 2003-2014. *Addict Behav*. 2017;65:229-235.
- Compton WM, Han B, Hughes A, **Jones CM**, Blanco C. Use of marijuana for medical purposes among adults in the United States. *JAMA* 2016; Jan 10;317(2):209-211.

2016

- **Jones CM**, Baldwin GT, Tefera L. State regulations and opioid use among disabled adults. *N Engl J Med*. 2016;375(14):1396-1397.
- Van Handell MM, Rose CE, Hallisey EJ, Kolling JL, Zibbell JE, Lewis B, Bohm MK, **Jones CM**, et al. County-level vulnerability assessment for rapid dissemination of HIV or HCV infections among persons who inject drugs, United States. *J Acquir Immune Defic Syndr*. 2016;73(3):323-331.
- **Jones CM**, Muhuri PK, Lurie PG. Trends in the Nonmedical Use of OxyContin, United States, 2006-2013. *Clin J Pain*. 2016. Aug 10.
- Easterling KW, Mack KA, **Jones CM**. Location of fatal prescription opioid-related deaths in 12 states, 2008-2010. Implications for prevention programs. *J Safety Res*. 2016;58:105-9.
- Compton WM, Han B, **Jones CM**, Blanco C, Hughes A. Marijuana Use and Use Disorders among Adults in the United States, 2002-2014; an analysis of annual cross-sectional surveys. *Lancet Psychiatry*. 2016. 3(10):954-964.
- El Burai Felix S, Mack KA, **Jones CM**. Trends in the distribution of opioids in Puerto Rick, 1999-2013. *PR Health Sci J*. 2016;35(3):165-9.
- Kattan JA, Tuazon E, Paone D, Dowell D, Vo L, Starrels JL, **Jones CM**, Kunins HV. Public health detailing – A successful strategy to promote judicious opioid analgesic prescribing. *Am J Public Health*. 2016;106(8):1430-8.
- **Jones CM**, Baldwin GT, Manocchio T, White JO, Mack KA. Trends in methadone distribution for pain treatment, methadone diversion, and overdose deaths, United States, 2002-2014. *Morb Mortal Wkly Rep*. 2016;65(26):667-71.
- **Jones CM**, Lurie PG, Compton WM. Increase in naloxone prescriptions dispensed in U.S. retail pharmacies since 2013. *Am J Public Health*. 2016;106(4):689-90.
- Hwang CS, Kang EM, Kornegay CJ, Staff JA, **Jones CM**, McAninch JK. Trends in the concomitant prescribing of opioids and benzodiazepines, 2002-2014. *Am J Prev Med*. 2016 Apr 11. Pii:S0749-3797(16)00094-5.
- Compton WM, **Jones CM**, Baldwin GT. Nonmedical prescription-opioid use and heroin use. *N Engl J Med*. 2016;374(13):1296
- Paulozzi LJ, Zhou C, **Jones CM**, Xu L, Florence CS. Changes in the medical management of patients on opioid analgesics following a diagnosis on substance abuse. *Pharmacoepidemiol Drug Saf*. 2016Feb 10. doi: 10.1002/pds.3980.
- **Jones CM**, Lurie PG, Throckmorton DC. Effect of US drug enforcement administration's rescheduling of hydrocodone combination analgesic products on opioid analgesic prescribing. *JAMA Internal Med*. 2016 Jan 25. doi: 10.1001/jamainternmed.2015.7799
- Compton WM, **Jones CM**, Baldwin GT. Relationship between nonmedical prescription-opioid use and heroin use. *N Engl J Med*. 2016;14:374:154-63.

2015

- Han B, Compton WM, **Jones CM**, Cai R. Nonmedical Prescription Opioid Use and Use Disorders Among Adults Aged 18 Through 64 Years in the United States, 2003-2013. *JAMA* 2015;314(14):1468-78.

- **Jones CM**, Logan J, Gladden RM, Bohm MK. Vital Signs: Demographic and Substance Use Trends Among Heroin Users – United States, 2002-2013. *MMWR Morb Mortal Wkly Rep.* 2015;64(26):719-25.
- **Jones CM**, Campopiano M, Baldwin G, McCance-Katz E. National and State Treatment Need and Capacity for Opioid Agonist Medication Assisted Treatment. *Am J Public Health* 2015 Aug;105(8):e55-63
- **Jones CM**, Mcanich JK. Emergency Department Visits and Overdose Deaths From Combined Use of Opioids and Benzodiazepines. *Am J Prev Med.* 2015;49(4):493-501.
- Levy B, Paulozzi L, Mack K, **Jones CM**. Trends in Opioid Analgesic Prescribing Rates by Specialty, United States, 2007-2012. *Am J Prev Med.* 2015 Apr 17. pii: S0749-3797(15)00089-6.
- Franklin G, Sabel J, **Jones CM**, et al. A Comprehensive Approach to Address the Prescription Opioid Epidemic in Washington State - Milestones and Lessons Learned. *Am Journal Public Health* 2015 Mar;105(3):463-9.
- Mack KA, Zhang K, Paulozzi LJ, **Jones CM**. Opioid Analgesic Prescriptions among Americans with Medicaid, 2010. *JHCPU.* 2014. *J Health Care Poor Underserved.* 2015;26(1):182-98.
- Yang Z, Wilsey B, Bohm M, et al. Defining Risk for Prescription Opioid Overdose: Pharmacy Shopping and Overlapping Prescriptions among Long-Term Opioid Users in Medicaid. *J Pain.* 2015 Feb 10 pii: S1526-5900(15)00530-1.

2014

- **Jones CM**, Paulozzi LJ, Mack KA. Alcohol involvement in opioid analgesic and benzodiazepine abuse-related emergency department visits and drug-related deaths, United States, 2010. *MMWR. Morbidity and mortality weekly report.* 10/2014; 63(40):881-885.
- **Jones CM**, Lurie P, Woodcock J. Addressing prescription opioid overdose – data support a comprehensive policy approach. 2014. *JAMA.* 2014 Nov 5;312(17):1733-4
- Haegerich T, Paulozzi LJ, Manns B, **Jones CM**. What we know, and don't know, about the impact of state policy and systems-level interventions on prescription drug overdose. *Drug and alcohol dependence* 12/2014; 145C:34-47. DOI: 10.1016/j.drugalcdep.2014.10.001.
- Mack KA, **Jones CM**. Prescription Analgesic Dispensing by Gender – United States, 2009-2014. *SAVIR Abstract.* 2014.
- Strickler G, Kriener P, Panas L., et al. Development and design of the Prescription Behavior Surveillance System (PBSS) preliminary results. 142nd APHA Annual Meeting and Exposition 2014; 11/2014
- Paulozzi LJ, Zhang K, **Jones CM**, Mack, KA. Risk of adverse health outcomes with increasing duration and regularity of opioid therapy. *J Am Board Fam Med.* 2014 May-Jun;27(3):329-38.
- Kattan J, Paone D, Dowell D., et al. Public health detailing as a successful strategy to change healthcare provider knowledge about opioid analgesic prescribing practices. 2014 Council of State and Territorial Epidemiologists Annual Conference; 06/2014
- Vo-Green L, Paone D, Kunins H. Public health detailing : a promising , innovative strategy to change opioid analgesic prescribing. 65th Society for Public Health Education Annual Conference, Baltimore, MD; 03/2014
- Faul M, Sugerman DE, Sasser SM, Levy BA, Paulozzi LJ, **Jones CM**. Factors that affect naloxone administration by emergency medical services providers following a drug overdose. *SAEM Abstracts* 2014;S32.

2013

- **Jones CM**, Paulozzi LJ, Mack KA. Source of prescription opioid pain relievers by frequency of past year nonmedical use, United States, 2008-2011. *JAMA Intern Med.* 2014 doi:10.1001/jamainternmed.2013.12809.
- Paulozzi LJ, Warner M, **Jones CM**. Defining controlled substances overdose: some challenges. *J Clin Toxicol* 2013;3:175. doi: 10.4172/2161-0495.1000175.
- Department of Health and Human Services. Addressing prescription drug abuse in the United States – current activities and future opportunities. 2013
- Department of Health and Human Services. Prescription drug monitoring program interoperability standards – A Report to Congress. 2013.
- Mack KA, **Jones CM**, Paulozzi LJ, Zhang K. Gender differences in opioid prescriptions among Americans with Medicaid. 141st APHA Annual Meeting and Exposition 2013; 11/2013
- Centers for Disease Control and Prevention. Patient review and restriction programs: lessons learned from state Medicaid programs. CDC Expert Panel meeting report. 2013.
- Berlin D, Farmer BM, Rao RB, Rella J, Kunins H, Dowell D, Graber N, Hoffman RS, Karpati A, Weiss D, **Jones CM**, Toprani A, Ridpath A. Deaths and severe adverse events associated with anesthesia-assisted rapid opioid detoxification – new york city, 2012. *MMWR* 2013;62(38):777-780.
- Smith S, Dart R, Katz N, et al. Classification and definition of misuse, abuse, and related events in clinical trials: ACTION systematic review and recommendations. *Pain*. 2013 pii: S0304-3959(13)00329-1. doi: 10.1016/j.pain.2013.05.053.
- Ying L, Logan J, Zhang K, **Jones CM**, Paulozzi L. Potential Misuse and Inappropriate Prescription Practices involving Opioid Analgesics among Commercially Insured Americans. *AJMC* 2013. *Am J Manag Care*. 2013;19(8):648-65.
- Mack KA, **Jones CM**, Paulozzi LJ. Vital Signs: Overdoses of Prescription Opioid Pain Relievers and Other Drugs Among Women - United States, 1999-2010. *MMWR Morb Mortal Wkly Rep*. 2013 Jul 5;62(26):537-542.
- Logan J, Ying L, Paulozzi L, Zhang K, **Jones CM**. Opioid prescribing in emergency departments: the prevalence of potentially inappropriate prescribing and misuse. *Med Care* 2013 Aug;51(8):646-53.
- **Jones CM**, Mack KA, Paulozzi LJ. Pharmaceutical Overdose Deaths, United States, 2010. *JAMA*. 2013 Feb 20;309(7):657-9.
- **Jones CM**. Heroin Use and Heroin Use Risk Behaviors Among Nonmedical Users of Opioid Pain Relievers, United States, 2002-2003 and 2008-2010. *Drug Alcohol Depend*. 2013 doi:pii: S0376-8716(13)00019-7. 10.1016/j.drugalcdep.2013.01.007.
- Modari F, Mack K, Hick P, Benoit S, Park S, **Jones C**, Proescholdbell S, Paulozzi L. Relationship of Opioid Prescription Sales and Overdoses, North Carolina. *Drug Alcohol Depend*. 2013 doi:pii: S0376-8716(13)00018-5. 10.1016/j.drugalcdep.2013.01.006.

2012

- Paulozzi LJ, Mack KM, **Jones CM**. Vital Signs: Risk for Overdose from Methadone Used for Pain Relief – United States, 1999-2010. *MMWR*, Jul 6;61:493-7. 2012.
- **Jones CM**. Frequency of prescription pain reliever nonmedical use: 2002-2003 and 2009-2010. *Arch Intern Med*. Jun 25;1-2. doi: 10.1001/archinternmed.2012.2533. 2012
- Popovich T, Paulozzi LJ, Baldwin G, **Jones CM**, Franklin G, Kerlikowske RG. CDC Grand Rounds: Prescription Drug Overdoses – A U.S. Epidemic. *CDC MMWR*. Vol 61, 10-13. 2012.

2011

- Paulozzi LJ, **Jones CM**, Mack KM, Rudd RA. Vital Signs: Overdoses of Prescription Opioid Pain Relievers – United States, 1999-2008. *CDC MMWR*. Vol 60, 1487–92. 2011.
- Office of National Drug Control Policy. National Drug Control Strategy 2011. Office of National Drug Control Policy, The White House. Washington, DC. 2011.
- Office of National Drug Control Policy. Epidemic: Responding to America’s Prescription Drug Abuse Crisis. Office of National Drug Control Policy, The White House. Washington, DC. 2011.
- Kerlikowske RG, **Jones CM**, LaBelle R, Condon TP. Prescription Drug Monitoring Programs – Lack of Effectiveness or Call To Action? *J Pain Med*. 12(5):687-689. 2011.

2008

- **Jones CM**. Pleiotropic Effects of Statins: A Panacea? *US Pharm*. 33(10):56-61. 2008.
- **Jones CM**, Earnhardt PI, Szczotka AD. Two Phased Physician and Patient Education Program to Improve Awareness of Controlled Substance Utilization in an Employer Group. *J Manag Care Pharm*. Abstract. 14:2;249. 2008.
- **Jones CM**. Thalidomide: New Cancer Uses for an Old Drug. *US Pharm*. 33(7)(Oncology suppl):3-13. 2008.
- **Jones CM**, Harshbarger J. Pediatric/Adolescent Vaccine Update. *US Pharm*. 33(3):28-47. 2008.
- **Jones CM**, Earnhardt PI. Targeted Therapy for Non-Small Cell Lung Cancer: An Update. *US Pharm*. 32(10):5-13. 2008.
- **Jones CM**. Acute Coronary Syndrome: A Primer for Pharmacists. *U.S. Pharm*. 32:2:52-57. 2008.

2007

- **Jones CM**. Sarcoidosis. *U.S. Pharm*. 32(7):HS-18-HS-25. 2007.

2006

- Kazzi ZN, **Jones CM**, Morgan BW. Seizures in a Pediatric Patient with a Tiagabine Overdose. *J Med Toxicology*. 2:4: 160-162. 2006.
- **Jones CM**, Nykamp DN. Vitamin E for the Prevention of Cardiovascular Disease? What Pharmacists Need to Know. *U.S. Pharm*. 31:10: 37-44. 2006.

2005

- Kazzi ZN, **Jones CM**, Craegin LS, Morgan B.W. Retrospective Review of Exposures to Tiagabine as Reported to a Regional Poison Center. *J Toxicol Clin Toxicol Abstract* 43(6):728. 2005.

2004

- Kazzi ZN, **Jones CM**, Hamilton E, Morgan BW Tiagabine Overdose in a Toddler Resulting in Seizure Activity. *J Toxicol Clin Toxicol Abstract* 42:721. 2004.

Awards and Honors:

- | | |
|--|----------|
| • PHS Unit Commendation | 2022 |
| • PHS COVID-19 Campaign Medal | 2021(EA) |
| • Presidential Unit Citation, PHS | 2021 |
| • PHS Unit Commendation | 2021 |
| • PHS COVID-19 Campaign Medal | 2020 |
| • PHS Unit Commendation | 2020 |
| • PHS Outstanding Unit Citation, HHS | 2020 |
| • PHS Outstanding Unit Citation, HHS | 2019 |
| • PHS Special Assignment Award, HHS | 2019 |
| • Secretary’s Distinguished Service Award, HHS | 2018 |

• Secretary's Meritorious Service Award, HHS	2018
• PHS Commissioned Corps, Exceptional Proficiency Promotion to O-6, Office of the Secretary	2017
• Secretary's Distinguished Service Award, HHS	2016
• Secretary's Distinguished Service Award, HHS	2015
• Presidential Unit Citation, PHS	2015
• Office of the Secretary Insignia Badge	2015
• Commendation Medal (PHS), Centers for Disease Control and Prevention (CDC)	2015
• Commendation Medal (PHS), Office of the Assistant Secretary for Health	2015
• CDC/NCIPC Directors Award	2014
• PHS Commissioned Corps, Exceptional Proficiency Promotion to O-5, CDC	2013
• CDC/NCIPC Excellence in Front Line Public Health Science Award	2013
• Unit Commendation (PHS), Office of the Surgeon General	2013
• Young Alumni Award, Mercer University School of Pharmacy	2012
• Achievement Medal (PHS), Centers for Disease Control and Prevention	2012
• Outstanding Service Medal (PHS), White House Office of National Drug Control Policy	2011
• Outstanding Unit Citation (PHS), Food and Drug Administration	2011
• Achievement Medal (PHS), Office of the Surgeon General	2011
• Unit Commendation (PHS), Food and Drug Administration	2011
• Unit Commendation (PHS), Food and Drug Administration	2011
• Special Assignment Award (PHS), Office of the Surgeon General	2011
• Dr. Frances Kelsey Drug Safety Excellence Award, Food and Drug Administration	2011
• Achievement Medal (PHS), Food and Drug Administration	2010
• PHS Citation (PHS), Assistant Secretary for Preparedness and Response	2010
• FDA Commissioner's Special Citation – H1N1 Flu response, Food and Drug Administration	2010
• Response Service Award (PHS), Office of the Surgeon General	2010
• JOAG Chair's Award	2010
• PharmPAC Letter of Appreciation	2010
• Commendation Medal (PHS), Food and Drug Administration	2009
• Achievement Medal (PHS), Food and Drug Administration	2009
• Field Medical Readiness Badge (PHS)	2009
• Commissioned Corps Training Ribbon	2009
• PharmPAC Certificate of Appreciation	2009
• JOAG Letter of Appreciation	2009
• JOAG Chair's Award	2009
• CDC Silo Busters: Collaborative Success Award, Pandemic Influenza Task Force	2007
• CDC/COTPER Directors Recognition Award	2007
• R.C Hood Award - Mercer University, Valedictorian for PharmD program	2006
• GlaxoSmithKline Patient Care Award - Mercer University	2006
• Phi Kappa Phi Academic Society	2005
• Oliver M. Littlejohn Award-Mercer University	2005
• Rho Chi Pharmaceutical Honor Society	2004
• Minnie Meyer Award - Mercer University	2004
• M. A. Chambers Award – Mercer University	2003

Professional Memberships and Activities:

• American Pharmacists Association	2016-Present
• Journal Reviewer JAMA	2014-Present

- Journal Reviewer American Journal of Public Health 2014-Present
- Journal Reviewer Drug and Alcohol Dependence 2014-Present
- Journal Reviewer American Journal of Preventive Medicine 2014-Present
- Mercer University College of Pharmacy and Health Sciences Board of Visitors 2012-2015
- Commissioned Officers Association 2009-2015
- American Public Health Association 2013-Present
- Adjunct Instructor, University of Maryland East. Shore School of Pharmacy 2011-2012
- Adjunct Instructor, Mercer University School of Pharmacy 2007-2010
- Adjunct Instructor, Univ. California San Diego School of Pharmacy 2009-2010
- American Association of Poison Control Centers 2003-2013
- American Society of Health Systems Pharmacists 2003-2006

License:

Georgia Registered Pharmacist License: RPH023229 2006-Present

Certifications and Special Skills:

- American Pharmacists Association Pharmacy Vaccine Program 2010-2017
- American Association of Poison Control Centers, Certified Poison Specialist 2008-2015
- Basic Life Support 2023